Abstract

Primary nephrotic syndrome (PNS) is a common kidney disease in children. The widespread use of glucocorticoids and other immunosuppressive agents has significantly improved the cure rate and survival rate of nephrotic syndrome patients. However, the complex pathophysiological mechanism of nephrotic syndrome and the long-term use of immunosuppressive agents such as glucocorticoids have led to the more prominent growth retardation in children with nephrotic syndrome, although the growth and development in childhood has an important influence on their heights at adult. There is no systematic and mature scheme for the prevention and treatment of short stature in children with PNS. The use of recombinant human growth hormone to treat short stature of children with PNS is currently the main means, but its safety and efficacy still need further researches for confirmation. Key words: Nephrotic syndrome; Short stature; Mechanism; Treatment

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.